The Medical Device Regulation (MDR) and the In Vitro Diagnostic Regulation (IVDR) coupled with Brexit (UKCA marking) have seen companies in the sector struggle to understand the changes and also to resource and ensure that their technical documentation complies.The risk is that devices will be delayed getting to market or if already on the market companies might lose their certification.
For any regulatory enquiries, please get in touch: [email protected]


Our Services
Since the publication of the MDR (EU 2017/745) and IVDR (EU 2017 / 746) we have developed a gap analysis service that uses a bespoke tool to audit compliance of your Technical File with the MDR. This includes three levels of service in which we provide a bronze level of support covering each element of your technical file during interactive sessions with verbal advice and feedback, through to our full gold service in which we provide an in-depth analysis of the technical documentation and a detailed report identifying gaps and recommendations with regard to how they can be addressed.
We can provide guidance, additional resource, or advice on your documentation, from the design history file that documents all the design and development activities to the technical documentation according to MDR 2017/745/ IVDR 2017/746.
Our training solutions range from introductory training covering the regulatory process (with a focus on UKCA and EU MDR), and types of technical documentation to more detailed courses and workshops covering the design history file, design control and technical file construction (including product labelling, information to be supplied by the manufacturer, design and manufacturing information), the General Safety and Performance Requirements (GSPRs), benefit risk analysis, risk management, clinical evaluation and post market surveillance requirements.
Our courses and workshops are tailored to your individual need and are designed to be interactive in which you benefit from bespoke consultancy during the sessions.
A Clinical Evaluation Report (CER) is a key component of the technical file and is used to support the intended purpose, product claims and to demonstrates that the benefits outweigh the risks.
The CER/ PER is a pivotal part of the technical documentation which is needed to both get a CE mark and also to maintain the product on the market.
The Medilink Team have extensive experience in authoring CERs.
Recent guidelines MDCG 2020-6 provide alternative means to for you to show conformity to the relevant General Safety and Performance Requirements (GSPRs) for legacy devices and might offer an alternative CER strategy to the conventional one described under MDR.
Our service includes:
- A CER strategy workshop which can help determine whether your device qualifies as a legacy device and to determine potential equivalence and similar products you can use. This will also cover the area of selection of products for benchmarking performance and safety.
- Full CER writing service.
Medilink have developed the MediPath Innovation Roadmap™ to help our clients plan their innovation journey to reduce risk, accelerate the speed to market, maximise the probability of market success and enhance profitability.
Drawing on our extensive experience and understanding of best practice, our team of experts have created a new tool to ensure that all key activities and milestones are considered. MediPath™ gives a comprehensive breakdown of all commercial, technical, clinical and regulatory actions, along with the associated resources, costs and time to get a medical device to market. See here for more information.
Testimonials
The Medilink Innovation and Commercialisation and Regulatory course was fantastic with relevant content bespoke to our request for training. The interactive content and innovation management tools will help us manage and optimise our portfolio. The learnings gained from this course have upskilled our entire team. Great course!
Medilink provided us with consultancy services which covered extending the intended purpose and product claims for one of our legacy devices. The work identified key user needs associated with using the device for a new clinical indication and has helped us articulate a series of new claims and has fed into our R&D projects in designing new predictive test methods, identifying the acceptability of the benefit risk ratio from competitor benchmarking and also input into our clinical evidence general plans. We look forward to working with Medilink in the future.
Medilink have authored a number of clinical evaluation reports for our family of class III implantable tissue regenerative products and we have been delighted in the speed and quality of the service and reports, which have also satisfied the notified body. We look forward to continuing our relationship with Medilink
Medilink has been instrumental in helping us navigate complex UK, EU, and US regulations, develop a compelling value proposition, and refine our product labelling and positioning strategy. The Medilink team also provided crucial guidance on planning and understanding the structure, as well as the primary and secondary endpoints, of future clinical trials—insights that will be invaluable for our resource allocation and strategic planning. Furthermore, they identified potential partners through thorough due diligence, assessing gaps in their portfolios and their preferred strategic approaches to growth. Medilink’s contribution has been invaluable in advancing our journey toward commercialization.
Let me first take this opportunity to thank you very much for your contributions over the past 2 years or so. Without this, our business unit would not be what it is today. The work you have completed sets a very high standard.
BioMin Technologies commissioned Medilink to author a Clinical Evaluation Report (CER) for a class IIB device technical file submission with a tight deadline and were delighted with both the quality and speed of the report. In fact, it’s the best overview and review of our product I have seen and we will use it for technical, marketing and other purposes. Many thanks to Medilink on a great job.
Medilink authored a development Clinical Evaluation Report and we were delighted with the quality of the work, it was comprehensive, insightful and also provided us with a much deeper understanding of alternative solutions and competitor products. We look forward to working with Medilink again in the future.
International Exhibitions
Medical Fair China + REHACARE China
Suzhou, ChinaMedical Fair Asia
SingaporeMedical Fair India | September 2026
Mumbai, IndiaREHACARE
Düsseldorf, GermanyAbu Dhabi Future Health Summit
Abu Dhabi, UAEMEDICA 2026
Düsseldorf, GermanyGet in Touch
"*" indicates required fields